Table 4.
Adjusted hazard ratio and incidence of meningioma by cumulative dosage of tamoxifen use in patients with breast cancer with and without tamoxifen use.
| Tamoxifen exposed | n | Event | Person-years | IR | Adjusted HR‡
(95% CI) |
Adjusted HR‡
(95% CI) |
|---|---|---|---|---|---|---|
| Without using tamoxifen | 30,929 | 35 | 116,553 | 3.00 | 1.00 | |
| Dosage of tamoxifen | ||||||
| ≤4280 mg | 12,621 | 6 | 35,169 | 1.71 | 0.54 (0.23, 1.31) | 1.00 |
| 4281–12,980 mg | 12,618 | 13 | 44,173 | 2.94 | 1.07 (0.55, 2.06) | 1.88 (0.71, 4.97) |
| 12,981–26,320 mg | 12,594 | 12 | 64,071 | 1.87 | 0.71 (0.36, 1.39) | 1.15 (0.43, 3.09) |
| >26,320 mg | 12,609 | 11 | 94,160 | 1.17 | 0.44 (0.22, 0.88)* | 0.68 (0.24, 1.87) |
CI, confidence interval; HR, hazard ratio; IR, incidence density rates (per 10,000 person-years). ‡Adjusted for age, aromatase inhibitor use, comorbidity, steroid use, statin use, thiazide diuretics use, treatment I, and treatment II. *P < 0.01.